PM to visit Serum Institute in Pune on Nov 28 to review vaccine development

Rao had also informed that ambassadors and envoys from 100 countries will visit the Serum Institute of India and the Gennova Biopharmaceuticals Ltd here on December 4

Modi
Photo: ANI
Press Trust of India Pune
2 min read Last Updated : Nov 26 2020 | 11:37 PM IST

Prime Minister Narendra Modi will on Saturday visit the Pune-based Serum Institute of India (SII), which has partnered with global pharma giant AstraZeneca and the Oxford University for COVID-19 vaccine, a senior official said on Thursday.

The Central Drug Standard Control Organisation has granted permission for manufacture of COVID-19 vaccine for pre-clinical test, examination and analysis to seven firms, two of which are the Serum Institute of India (SII) and the Gennova Biopharmaceuticals.

"We have received a confirmation about PM Modi's visit to the Serum Institute of India on Saturday," Pune Divisional Commissioner Saurabh Rao said.

"The PM will arrive at the Pune airport at 12.30 pm on Saturday. He will attend the scheduled programme at the Serum Institute of India from 1 pm to 2 pm, where he will review the mechanism of COVID-19 vaccine production and its distribution," he said.

Ahead of the PM's visit, a Special Protection Group (SPG) team has arrived in the city for security arrangements and the local machinery, including the police, fire brigade, departments of revenue, PWD and health, are coordinating.

On Tuesday, Rao said there was a possibility of the PM's visit to Pune, and if that happens, it would be aimed at reviewing the status of the vaccine candidate for coronavirus infection and to know about its launch, production and distribution mechanisms.

Rao had also informed that ambassadors and envoys from 100 countries will visit the Serum Institute of India and the Gennova Biopharmaceuticals Ltd here on December 4.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Narendra ModiSerum Institute of IndiaCoronavirus Vaccine

First Published: Nov 26 2020 | 11:09 PM IST

Next Story